Evidence Amyloid Scan EEG Study

Status unconfirmed

Conditions studied: Alzheimer Disease, Dementia Frontal, Mild Cognitive Impairment

In brief

The Evidence Amyloid Study EEG (EASE) establishes an open-label, longitudinal cohort study to measure of neurological functioning during the onset and progression of cognitive decline in preclinical Alzheimer's patients using quantitative electroencephalography (qEEG) measures (P300, P50, and reaction time). Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi headset with the WAVi EEG P300/P50 system, along with the structured clinical interviews and assessments for baseline screening or mild cognitive impairment which are standard of care.

Key facts

Study ID
NCT03644043
Run by
Metabolic Therapy Inc.
People needed
2000
Starts
2018-07-20
Expected to finish
2020-11-30
Last updated by the study team
2018-08-23

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.